Anti-prostatic disease

Atraric acid
Catalog No: CFN98703

Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases. It inhibits PTP1B activity in a dose-dependent manner with IC50 values of 51.5 uM, suggest that atraric acid has potential to treat diabetes.

Grandifloroside
Catalog No: CFN97045

Grandifloroside shows good antioxidative and potent anti-inflammatory activities, it also exhibits potent inhibitory activity against TNF-α and 5α-reductase, suggests that it might be developed as a source of potent anti-oxidative and anti-inflammatory agents and therapeutic agent for benign prostatic hypertrophy (BPH).

6-Hydroxy-5,6-dehydrosugiol
Catalog No: CFN92149

6-Hydroxy-5,6-dehydrosugiol is a potent androgen receptor antagonist in prostate cancer cells, it has potential for use in chemoprevention and chemotherapy of prostate cancers.

Eriosemation
Catalog No: CFN92835

Eriosemation significant androgen receptor (AR) inhibition activity, suggests that it could be a promising candidate for further evaluation for prostate cancer prevention or management.

Tomatine
Catalog No: CFN90930

Tomatine is a natural glycoalkaloid with anti-inflammatory, fungicidal, antimicrobial, and insecticidal properties. alpha-Tomatine activates phosphotyrosine kinase and monomeric G-protein signaling pathways leading to Ca(2+) elevation and ROS burst in F. oxysporum cells.